QNCX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 22:00):

Stats
Dagens volum	25 682.00
Gjennomsnittsvolum	72 125.00
Markedsverdi	45.59M
EPS	$0 ( 2024-04-02 )
Neste inntjeningsdato	( $0 ) 2024-06-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.260
ATR14	$0.00600 (0.57%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-15	Patni Rajiv	Buy	54 000	Employee Stock Option (right to buy)
2024-02-15	Patni Rajiv	Buy	0
2024-02-01	Ryan Charles S.	Buy	145 000	Employee Stock Option (right to buy)
2024-02-01	Hannah Brendan	Buy	600 000	Employee Stock Option (right to buy)
2024-02-01	Thye Dirk	Buy	1 500 000	Employee Stock Option (right to buy)

INSIDER POWER
90.02
Last 72 transactions
Buy: 5 607 188 \| Sell: 249 899

Volum Korrelasjon

Lang: -0.04 (neutral)

Kort: 0.99 (very strong)

Signal:(52.218) Expect same movement, but be aware

Quince Therapeutics, Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Quince Therapeutics, Inc. Korrelasjon - Valuta/Råvare

0.25
( neutral )

0.34
( neutral )

0.00
( neutral )

-0.19
( neutral )

-0.11
( neutral )

Quince Therapeutics, Inc. Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-322 000 (0.00 %)
EPS:	$-0.840

FY	2023
Omsetning:	$0
Bruttogevinst:	$-322 000 (0.00 %)
EPS:	$-0.840

FY	2022
Omsetning:	$0
Bruttogevinst:	$-175 000 (0.00 %)
EPS:	$-1.540

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-3.02

Financial Reports:

No articles found.

Quince Therapeutics, Inc.

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.